BB&T Securities’s Nektar Therapeutics NKTR Stock Holding History

BB&T Securities’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-400	Closed	-$365K	–	1568
2018 Q3	$365K	Buy	+400	New	+$341K	﹤0.01%	1240

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BB&T Securities's NKTR Position: Q3 2019 in Review

BB&T Securities sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 531 shares — an estimated $283K sold.

BB&T Securities first reported a position in NKTR in Q1 2018 and held it in 6 quarters. The position peaked at $698K in Q3 2018. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

BB&T Securities reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
BB&T Securities sold 531 Nektar Therapeutics shares in Q3 2019, an estimated $283K.
BB&T Securities first reported a position in Nektar Therapeutics in Q1 2018 and held it in 6 quarters.
BB&T Securities's Nektar Therapeutics position peaked at $698K in Q3 2018.
287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.